Michelle Fillion, MD
Surgical Oncology · Wilmington, NCNPI 1871758235
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $862, 3.5 times the $244 reported in 2019.
Across 92 payments — averaging $31.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$644
- Smith+Nephew$234
- Intuitive Surgical$230
- AbbVie$227
- Merck$210
- AstraZeneca$129
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,83897%
- Education$682%
- Entertainment$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 12 | $644 |
| Smith+Nephew | 11 | $234 |
| Intuitive Surgical | 5 | $230 |
| AbbVie | 5 | $227 |
| Merck | 10 | $210 |
| AstraZeneca(2 entities) | 4 | $129 |
| Boston Scientific | 3 | $108 |
| Integra Lifesciences Corporation | 1 | $104 |
| Covidien LP | 2 | $103 |
| Daiichi Sankyo Inc. | 4 | $95 |
| Convatec Inc. | 1 | $90 |
| Angiodynamics, Inc. | 1 | $88 |
| Acell, Inc. | 4 | $75 |
| Eisai Inc. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Foundation Medicine, Inc. | 2 | $38 |
| Kerecis Limited | 1 | $38 |
| Genentech USA, Inc. | 2 | $36 |
| Davol Inc. | 2 | $33 |
| Atricure, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| AVEO Pharmaceuticals, Inc. | 1 | $26 |
| Fennec Pharmaceuticals, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $22 |
| Sanara Medtech Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| Beigene USA, Inc. | 1 | $20 |
| Sobi, Inc | 1 | $18 |
| Geron Corporation | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| GSK | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Solventum Corporation | 1 | $15 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,928 in reported general payments places this provider in the 55th percentile of 34 surgical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 18 | $67,882 |
| CreonLipase/Protease/Amylase | 11 | $25,005 |
| Oxycodone Hcl | 32 | $123 |
| Pantoprazole Sodium | 13 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $227 | $25,00511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 34 surgical oncology providers in North Carolina.
Other surgical oncology in Wilmington
- Kristalyn GallagherChapel Hill$54K
- Georgia BeasleyDurham$23K
- Hong Jin KimChapel Hill$22K
- Akiko ChibaWinston Salem$14K
- Mark ArredondoHigh Point$13K
- Kevin ShahDurham$12K
- Allison MartinDurham$10K
- Princess WilliamsMooresville$9K
- Jen Jen YehChapel Hill$8K
- Daniel NussbaumDurham$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.